Kenai Therapeutics Emerges with $82M to Advance Its Allogeneic, iPSC-Derived Therapy for Parkinson’s Disease
Kenai Therapeutics has emerged from stealth mode with $82M to invest in its allogeneic iPSC-derived cell therapeutic for Parkinson’s disease (PD).
Proceeds to be used to complete clinical proof-of-concept trial for Kenai’s lead candidate, RNDP-001, for the treatment of Parkinson’s disease.
Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.
Waisman Biomanufacturing & RoosterBio Announce Collaboration for GMP Manufacturing of Cell & Exosome Therapies
Madison, WI — Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services. [Read more…]
New “Placental Tissue Amendment” Bill Clarifies Disclosures Required to Perform Stem Cell Therapies in Utah
The “Placental Tissue Amendment Bill”, Part of SB 0199, Has Been Passed by the Utah State Legislature.
The “Placental Tissue Amendment Bill“, part of SB 0199, recently passed by the Utah State Legislature, introduces specific requirements for healthcare providers administering treatments involving placental stem cells. The key focus of this bill is to ensure that patients receive adequate disclosures regarding the nature of the treatment, particularly if it involves stem cell therapy that hasn’t been approved by the United States Food and Drug Administration (FDA). [Read more…]
Novo Holdings to Acquire the CDMO Catalent for a Staggering $16.5 Billion Enterprise Value
Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024
COPENHAGEN, Denmark and SOMERSET, N.J. – February 5, 2024– Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, announced that they entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. [Read more…]
- « Previous Page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- …
- 338
- Next Page »